socalTECH

NOVEMBER 9, 2020

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.

Arcturus 113

Arcturus Study San Diego Funding 113

socalTECH

OCTOBER 21, 2013

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. READ MORE>>.

Arcturus 153

Arcturus San Diego .Net Venture Capital 153

socalTECH

JUNE 3, 2013

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech'

Arcturus 138

Arcturus San Diego .Net Venture Capital 138

Xconomy

APRIL 17, 2020

Alnylam had sold the drug’s development and commercialization rights seven years ago. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Now in the hands of Novartis (NYSE: NVS ), the potential blockbuster seller awaits an FDA decision.

Equity 84

Equity Activity Marketing Company 84